[미국특허]
Identification and use of novopeptides for the treatment of cancer
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
C07K-014/47
C12Q-001/68
G01N-033/50
A61K-048/00
출원번호
US-0451374
(2014-08-04)
등록번호
US-9732131
(2017-08-15)
발명자
/ 주소
Johnston, Stephen Albert
출원인 / 주소
CALVIRI, INC.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
0인용 특허 :
21
초록
Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto.
대표청구항▼
1. A vaccine, comprising a continuous amino acid chain, or a continuous portion thereof, according to the formula D1-D2, and an effective amount of an adjuvant, wherein D1 and D2 each comprise a polypeptide sequence encoded by a different exon or continuous portion thereof of a genome, wherein D1 is
1. A vaccine, comprising a continuous amino acid chain, or a continuous portion thereof, according to the formula D1-D2, and an effective amount of an adjuvant, wherein D1 and D2 each comprise a polypeptide sequence encoded by a different exon or continuous portion thereof of a genome, wherein D1 is encoded in a wild type reading frame and D2 is encoded in a non-wild type reading frame and wherein D2 has a sequence selected from: peptide 1-78 (SEQ ID NO: 295), peptide 6-21 (SEQ ID NO:291), peptide RBM (SEQ ID NO: 232), peptide THAP2 (SEQ ID NO: 238), and combinations thereof, wherein the adjuvant is selected from the group consisting of an alum, a CpG, a KLH, an oil emulsion, and combinations thereof. 2. The vaccine of claim 1, wherein the portion of D1 immediately adjacent to D2 is not a microsatellite or portion thereof. 3. The vaccine of claim 1, wherein neither of the different exons is an oncogene. 4. The vaccine of claim 1, wherein a RefSeq of the mammalian species does not contain a continuous nucleic acid sequence encoding the sequence of the continuous amino acid chain. 5. The vaccine of claim 1, wherein a normal transcriptome of the mammalian species does not contain a continuous nucleic acid sequence encoding the sequence of the continuous amino acid chain. 6. The vaccine of claim 1, wherein the continuous amino acid chain aligns with at least 90% identity to all or a portion of an mRNA transcript expressed in at least one cancer type of a mammalian species. 7. The vaccine of claim 1, wherein the continuous amino acid chain has a cancer association ratio of at least 2:1 with respect to at least one cancer type of a mammalian species. 8. The vaccine of claim 1, wherein the continuous amino acid chain has a cancer serum recognition percentage of at least 40% with respect to at least one cancer type of a mammalian species. 9. The vaccine of claim 1, wherein the continuous amino acid chain is capable of being displayed in a Class I major histocompatibiity complex (MHC-I) of a type expressed by at least 4 percent of a population. 10. A method comprising administering to a mammal an effective dose of the vaccine of claim 1. 11. The vaccine of claim 1 wherein the continuous amino acid chain is encoded by a synthetic or recombinant nucleic acid. 12. The vaccine of claim 11, wherein the continuous amino acid chain comprises a first peptide component displayable in a first MHC type expressed in a first cohort of the population and a second peptide component displayable in a second MHC type expressed in a second cohort of the population, and the first and second cohort together are more numerous by at least 2 percent of the population than either cohort taken separately. 13. A method comprising administering to a mammal by genetic immunization an effective dose of the vaccine of claim 11. 14. A method comprising administering to a mammal by genetic immunization an effective dose of the vaccine of claim 12. 15. A method comprising: (a) administering to a mammal by genetic immunization an effective dose of the vaccine of claim 1, wherein the continuous amino acid chain is encoded by a synthetic or recombinant nucleic acid, an adjuvant, and a carrier adapted for administration of the vaccine by genetic immunization; and(b) administering to the mammal an effective dose of the vaccine, in a pharmaceutically acceptable carrier. 16. The method of claim 15, wherein step (b) is performed at least two weeks after step (a). 17. A vector comprising a promoter and a nucleic acid encoding a continuous amino acid chain, or a continuous portion thereof, according to the formula D1-D2, wherein D1 and D2 each comprise a polypeptide sequence encoded by a different exon or continuous portion thereof of a genome, wherein D1 is encoded in a wild type reading frame and D2 is encoded in a non-wild type reading frame and wherein D2 has a sequence selected from: peptide 1-78 (SEQ ID NO: 295), peptide 6-21 (SEQ ID NO:291), peptide RBM (SEQ ID NO: 232), peptide THAP2 (SEQ ID NO: 238), and combinations thereof. 18. The vaccine of claim 17, wherein the vector further comprises a nucleic acid encoding an adjuvant selected from a KLH, a GMCSF, an interleukin, and combinations thereof.
Von Knebel-Doeberitz, Magnus; Gebert, Johannes; Linnebacher, Michael; Woerner, Stefan; Ridder, Ruediger; Bork, Peer; Yuan, Yan Ping, Compounds and methods useful for detection and treatment of cancer.
Cheever Martin A. (Mercer Island WA) Peace David J. (Seattle WA), Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins.
Von Knebel-Doeberitz, Magnus; Gebert, Johannes; Linnebacher, Michael; Woerner, Stefan; Ridder, Ruediger; Bork, Peer; Yuan, Yan Ping, Neopeptides and methods useful for detection and treatment of cancer.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.